{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:12:58Z","timestamp":1792537978683,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40259-024-00684-z","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T09:02:36Z","timestamp":1729155756000},"page":"795-819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2853-2896","authenticated-orcid":false,"given":"Chae Sung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Maski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"issue":"3","key":"684_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1042\/ebc20200108","volume":"66","author":"R Morris","year":"2022","unstructured":"Morris R, Black KA, Stollar EJ. Uncovering protein function: from classification to complexes. Essays Biochem. 2022;66(3):255\u201385. https:\/\/doi.org\/10.1042\/ebc20200108.","journal-title":"Essays Biochem"},{"issue":"51","key":"684_CR2","doi-asserted-by":"publisher","first-page":"35947","DOI":"10.1039\/d3ra06476j","volume":"13","author":"M Rahban","year":"2023","unstructured":"Rahban M, Ahmad F, Piatyszek MA, Haertl\u00e9 T, Saso L, Saboury AA. Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry. RSC Adv. 2023;13(51):35947\u201363. https:\/\/doi.org\/10.1039\/d3ra06476j.","journal-title":"RSC Adv"},{"issue":"1","key":"684_CR3","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/s41467-023-38039-x","volume":"14","author":"SB Ebrahimi","year":"2023","unstructured":"Ebrahimi SB, Samanta D. Engineering protein-based therapeutics through structural and chemical design. Nat Commun. 2023;14(1):2411. https:\/\/doi.org\/10.1038\/s41467-023-38039-x.","journal-title":"Nat Commun"},{"issue":"1","key":"684_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10600","volume":"9","author":"Y Gao","year":"2024","unstructured":"Gao Y, Joshi M, Zhao Z, Mitragotri S. PEGylated therapeutics in the clinic. Bioeng Transl Med. 2024;9(1): e10600. https:\/\/doi.org\/10.1002\/btm2.10600.","journal-title":"Bioeng Transl Med."},{"issue":"3","key":"684_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12079-018-0492-0","volume":"13","author":"V Gupta","year":"2019","unstructured":"Gupta V, Bhavanasi S, Quadir M, et al. Protein PEGylation for cancer therapy: bench to bedside. J Cell Commun Signal. 2019;13(3):319\u201330. https:\/\/doi.org\/10.1007\/s12079-018-0492-0.","journal-title":"J Cell Commun Signal."},{"key":"684_CR6","doi-asserted-by":"publisher","first-page":"8929715","DOI":"10.1155\/2022\/8929715","volume":"2022","author":"LK Zuma","year":"2022","unstructured":"Zuma LK, Gasa NL, Makhoba XH, Pooe OJ. Protein PEGylation: navigating recombinant protein stability, aggregation, and bioactivity. Biomed Res Int. 2022;2022:8929715. https:\/\/doi.org\/10.1155\/2022\/8929715.","journal-title":"Biomed Res Int"},{"key":"684_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114079","volume":"180","author":"D Shi","year":"2022","unstructured":"Shi D, Beasock D, Fessler A, et al. To PEGylate or not to PEGylate: Immunological properties of nanomedicine\u2019s most popular component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev. 2022;180: 114079. https:\/\/doi.org\/10.1016\/j.addr.2021.114079.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"684_CR8","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/s2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196\u2013208. https:\/\/doi.org\/10.1016\/s2352-3026(19)30236-4.","journal-title":"Lancet Haematol."},{"issue":"4","key":"684_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/s0169-409x(02)00028-5","volume":"54","author":"K Rajender Reddy","year":"2002","unstructured":"Rajender Reddy K, Modi MW, Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev. 2002;54(4):571\u201386. https:\/\/doi.org\/10.1016\/s0169-409x(02)00028-5.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"684_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/jcm6040039","volume":"6","author":"ME Mancuso","year":"2017","unstructured":"Mancuso ME, Santagostino E. Outcome of clinical trials with new extended half-life FVIII\/IX concentrates. J Clin Med. 2017;6(4):39. https:\/\/doi.org\/10.3390\/jcm6040039.","journal-title":"J Clin Med"},{"issue":"34","key":"684_CR11","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1200\/jco.2014.55.5763","volume":"32","author":"AL Angiolillo","year":"2014","unstructured":"Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli l-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children\u2019s Oncology Group Study AALL07P4. J Clin Oncol. 2014;32(34):3874\u201382. https:\/\/doi.org\/10.1200\/jco.2014.55.5763.","journal-title":"J Clin Oncol"},{"issue":"9633","key":"684_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s0140-6736(08)61033-8","volume":"372","author":"AM Eggermont","year":"2008","unstructured":"Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117\u201326. https:\/\/doi.org\/10.1016\/s0140-6736(08)61033-8.","journal-title":"Lancet"},{"issue":"16","key":"684_CR13","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/s1470-2045(15)00363-0","volume":"16","author":"AE Place","year":"2015","unstructured":"Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05\u2013001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677\u201390. https:\/\/doi.org\/10.1016\/s1470-2045(15)00363-0.","journal-title":"Lancet Oncol"},{"issue":"12","key":"684_CR14","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/inf.0000000000002876","volume":"39","author":"Y He","year":"2020","unstructured":"He Y, Yin J, Xu H. Efficacy and safety of pegylated interferon for the treatment of chronic hepatitis B in children and adolescents: a systematic review and meta-analysis. Pediatr Infect Dis J. 2020;39(12):1121\u20136. https:\/\/doi.org\/10.1097\/inf.0000000000002876.","journal-title":"Pediatr Infect Dis J"},{"key":"684_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jconrel.2022.09.031","volume":"351","author":"M Ibrahim","year":"2022","unstructured":"Ibrahim M, Ramadan E, Elsadek NE, et al. Polyethylene glycol (PEG): the nature, immunogenicity, and role in the hypersensitivity of PEGylated products. J Control Release. 2022;351:215\u201330. https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.031.","journal-title":"J Control Release"},{"issue":"8","key":"684_CR16","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","volume":"16","author":"Y Ju","year":"2022","unstructured":"Ju Y, Lee WS, Pilkington EH, et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano. 2022;16(8):11769\u201380. https:\/\/doi.org\/10.1021\/acsnano.2c04543.","journal-title":"ACS Nano"},{"issue":"23","key":"684_CR17","doi-asserted-by":"publisher","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","volume":"88","author":"Q Yang","year":"2016","unstructured":"Yang Q, Jacobs TM, McCallen JD, et al. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal Chem. 2016;88(23):11804\u201312. https:\/\/doi.org\/10.1021\/acs.analchem.6b03437.","journal-title":"Anal Chem"},{"key":"684_CR18","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/ijn.S30943","volume":"7","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Wang L, Yan M, et al. Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles. Int J Nanomed. 2012;7:2891\u2013900. https:\/\/doi.org\/10.2147\/ijn.S30943.","journal-title":"Int J Nanomed"},{"issue":"5","key":"684_CR19","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","volume":"137","author":"NJ Ganson","year":"2016","unstructured":"Ganson NJ, Povsic TJ, Sullenger BA, et al. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol. 2016;137(5):1610-1613.e7. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.034.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"684_CR20","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.7150\/thno.22164","volume":"8","author":"YC Hsieh","year":"2018","unstructured":"Hsieh YC, Wang HE, Lin WW, et al. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes. Theranostics. 2018;8(11):3164\u201375. https:\/\/doi.org\/10.7150\/thno.22164.","journal-title":"Theranostics."},{"key":"684_CR21","unstructured":"Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane, 2023. Updated August 2023. www.training.cochrane.org\/handbook. Accessed 8 Aug 2024."},{"issue":"1","key":"684_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3892\/ol.2017.7271","volume":"15","author":"J Liang","year":"2018","unstructured":"Liang J, Shi P, Guo X, et al. A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia. Oncol Lett. 2018;15(1):75\u201382. https:\/\/doi.org\/10.3892\/ol.2017.7271.","journal-title":"Oncol Lett"},{"issue":"8","key":"684_CR23","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/annonc\/mdw225","volume":"27","author":"TK Eigentler","year":"2016","unstructured":"Eigentler TK, Gutzmer R, Hauschild A, et al. Adjuvant treatment with pegylated interferon \u03b1-2a versus low-dose interferon \u03b1-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. Ann Oncol. 2016;27(8):1625\u201332. https:\/\/doi.org\/10.1093\/annonc\/mdw225.","journal-title":"Ann Oncol"},{"key":"684_CR24","doi-asserted-by":"publisher","first-page":"CD005441","DOI":"10.1002\/14651858.CD005441.pub3","volume":"2","author":"G Hauser","year":"2014","unstructured":"Hauser G, Awad T, Brok J, et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database Syst Rev. 2014;2:CD005441. https:\/\/doi.org\/10.1002\/14651858.CD005441.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"684_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejca.2012.07.018","volume":"49","author":"JJ Grob","year":"2013","unstructured":"Grob JJ, Jouary T, Dr\u00e9no B, et al. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Eur J Cancer. 2013;49(1):166\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2012.07.018.","journal-title":"Eur J Cancer"},{"issue":"10","key":"684_CR26","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1365-2036.2007.03294.x","volume":"25","author":"M Simin","year":"2007","unstructured":"Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther. 2007;25(10):1153\u201362. https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03294.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"684_CR27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/135965350400900417","volume":"9","author":"M Puoti","year":"2004","unstructured":"Puoti M, Babudieri S, Rezza G, et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther. 2004;9(4):627\u201330.","journal-title":"Antivir Ther"},{"issue":"11","key":"684_CR28","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/dom.12698","volume":"18","author":"RM Bergenstal","year":"2016","unstructured":"Bergenstal RM, Lunt H, Franek E, et al. Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes Metab. 2016;18(11):1081\u20138. https:\/\/doi.org\/10.1111\/dom.12698.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 2","key":"684_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/dom.12738","volume":"18","author":"S Garg","year":"2016","unstructured":"Garg S, Dreyer M, Jinnouchi H, et al. A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1. Diabetes Obes Metab. 2016;18(Suppl 2):25\u201333. https:\/\/doi.org\/10.1111\/dom.12738.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"684_CR30","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1080\/10428194.2017.1397661","volume":"59","author":"JM Ribera","year":"2018","unstructured":"Ribera JM, Morgades M, Montesinos P, et al. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(7):1634\u201343. https:\/\/doi.org\/10.1080\/10428194.2017.1397661.","journal-title":"Leuk Lymphoma"},{"key":"684_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/jrms.JRMS_463_17","volume":"23","author":"F Ashrafi","year":"2018","unstructured":"Ashrafi F, Salmasi M. Comparison of the effects of pegylated granulocyte-colony stimulating factor and granulocyte-colony stimulating factor on cytopenia induced by dose-dense chemotherapy in breast cancer patients. J Res Med Sci. 2018;23:73. https:\/\/doi.org\/10.4103\/jrms.JRMS_463_17.","journal-title":"J Res Med Sci"},{"key":"684_CR32","doi-asserted-by":"publisher","first-page":"adv00722","DOI":"10.2340\/actadv.v102.2487","volume":"102","author":"JD Albrecht","year":"2022","unstructured":"Albrecht JD, Ninosu N, Barry D, et al. Non-PEGylated and pegylated interferon alpha-2a in cutaneous T-cell lymphoma and the risk of severe ocular side-effects. Acta Derm Venereol. 2022;102:adv00722. https:\/\/doi.org\/10.2340\/actadv.v102.2487.","journal-title":"Acta Derm Venereol"},{"issue":"23","key":"684_CR33","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1200\/jco.18.02439","volume":"37","author":"Y Liu","year":"2019","unstructured":"Liu Y, Smith CA, Panetta JC, et al. Antibodies predict pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019;37(23):2051\u201361. https:\/\/doi.org\/10.1200\/jco.18.02439.","journal-title":"J Clin Oncol"},{"issue":"4","key":"684_CR34","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1440-1746.2005.03795.x","volume":"20","author":"P Toniutto","year":"2005","unstructured":"Toniutto P, Fabris C, Fumo E, et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy. J Gastroenterol Hepatol. 2005;20(4):577\u201382. https:\/\/doi.org\/10.1111\/j.1440-1746.2005.03795.x.","journal-title":"J Gastroenterol Hepatol"},{"issue":"21","key":"684_CR35","doi-asserted-by":"publisher","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","volume":"88","author":"BM Chen","year":"2016","unstructured":"Chen BM, Su YC, Chang CJ, et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal Chem. 2016;88(21):10661\u20136. https:\/\/doi.org\/10.1021\/acs.analchem.6b03109.","journal-title":"Anal Chem"},{"key":"684_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.toxrep.2020.12.022","volume":"8","author":"JL Fang","year":"2021","unstructured":"Fang JL, Beland FA, Tang Y, Roffler SR. Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma. Toxicol Rep. 2021;8:148\u201354. https:\/\/doi.org\/10.1016\/j.toxrep.2020.12.022.","journal-title":"Toxicol Rep"},{"issue":"1","key":"684_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3324\/haematol.2020.258525","volume":"107","author":"A Khalil","year":"2022","unstructured":"Khalil A, W\u00fcrthwein G, Golitsch J, et al. Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia. Haematologica. 2022;107(1):49\u201357. https:\/\/doi.org\/10.3324\/haematol.2020.258525.","journal-title":"Haematologica"},{"issue":"9","key":"684_CR38","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s11095-016-1961-x","volume":"33","author":"C Lubich","year":"2016","unstructured":"Lubich C, Allacher P, de la Rosa M, et al. The mystery of antibodies against polyethylene glycol (PEG)\u2014what do we know? Pharm Res. 2016;33(9):2239\u201349. https:\/\/doi.org\/10.1007\/s11095-016-1961-x.","journal-title":"Pharm Res"},{"issue":"2","key":"684_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13318-021-00741-w","volume":"47","author":"C Siebel","year":"2022","unstructured":"Siebel C, Lanvers-Kaminsky C, Alten J, et al. Impact of antibodies against polyethylene glycol on the pharmacokinetics of PEGylated asparaginase in children with acute lymphoblastic leukaemia: a population pharmacokinetic approach. Eur J Drug Metab Pharmacokinet. 2022;47(2):187\u201398. https:\/\/doi.org\/10.1007\/s13318-021-00741-w.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"684_CR40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/cncr.22739","volume":"110","author":"JK Armstrong","year":"2007","unstructured":"Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110(1):103\u201311. https:\/\/doi.org\/10.1002\/cncr.22739.","journal-title":"Cancer"},{"issue":"2","key":"684_CR41","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar4500","volume":"16","author":"MS Hershfield","year":"2014","unstructured":"Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther. 2014;16(2):R63. https:\/\/doi.org\/10.1186\/ar4500.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"684_CR42","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1016\/j.jtha.2023.07.019","volume":"21","author":"A Hillarp","year":"2023","unstructured":"Hillarp A, Holme PA, W\u00e5land EP, et al. Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII. J Thromb Haemost. 2023;21(10):2771\u20135. https:\/\/doi.org\/10.1016\/j.jtha.2023.07.019.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"684_CR43","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/bjh.16254","volume":"189","author":"R Kloos","year":"2020","unstructured":"Kloos R, van der Sluis IM, Mastrobattista E, Hennink W, Pieters R, Verhoef JJ. Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker. Br J Haematol. 2020;189(3):442\u201351. https:\/\/doi.org\/10.1111\/bjh.16254.","journal-title":"Br J Haematol"},{"issue":"9","key":"684_CR44","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.4155\/bio.15.36","volume":"7","author":"H Myler","year":"2015","unstructured":"Myler H, Hruska MW, Srinivasan S, et al. Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN-\u03bb-1a and PEG-IFN-\u03b12a in naive patients. Bioanalysis. 2015;7(9):1093\u2013106. https:\/\/doi.org\/10.4155\/bio.15.36.","journal-title":"Bioanalysis"},{"issue":"6","key":"684_CR45","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jtha.2023.03.011","volume":"21","author":"B Pezeshkpoor","year":"2023","unstructured":"Pezeshkpoor B, Sereda N, Berkemeier AC, et al. Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII. J Thromb Haemost. 2023;21(6):1503\u201314. https:\/\/doi.org\/10.1016\/j.jtha.2023.03.011.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"684_CR46","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/art.22403","volume":"56","author":"JS Sundy","year":"2007","unstructured":"Sundy JS, Ganson NJ, Kelly SJ, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007;56(3):1021\u20138. https:\/\/doi.org\/10.1002\/art.22403.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"684_CR47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40264-023-01277-5","volume":"46","author":"S Crisafulli","year":"2023","unstructured":"Crisafulli S, Cutroneo PM, Luxi N, et al. Is PEGylation of drugs associated with hypersensitivity reactions? An analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System. Drug Saf. 2023;46(4):343\u201355. https:\/\/doi.org\/10.1007\/s40264-023-01277-5.","journal-title":"Drug Saf"},{"key":"684_CR48","unstructured":"Bayer HealthCare LLC. JIVI US prescribing information. 2018."},{"issue":"9","key":"684_CR49","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2146\/ajhp130571","volume":"71","author":"WM Gentry","year":"2014","unstructured":"Gentry WM, Dotson MP, Williams BS, et al. Investigation of pegloticase-associated adverse events from a nationwide reporting system database. Am J Health Syst Pharm. 2014;71(9):722\u20137. https:\/\/doi.org\/10.2146\/ajhp130571.","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"684_CR50","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","volume":"21","author":"M Chen","year":"2016","unstructured":"Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today. 2016;21(4):648\u201353. https:\/\/doi.org\/10.1016\/j.drudis.2016.02.015.","journal-title":"Drug Discov Today"},{"key":"684_CR51","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211215Orig1s000MedR.pdf. Accessed 8 Aug 2024."},{"key":"684_CR52","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761161Orig1s000MultidisciplineR.pdf. Accessed 8 Aug 2024."},{"key":"684_CR53","unstructured":"Chiesi Farmaceutici S.p.A. Elfabrio US prescribing information. 2023. https:\/\/resources.chiesiusa.com\/Elfabrio\/ELFABRIO_PI.pdf. Accessed 8 Aug 2024."},{"key":"684_CR54","unstructured":"Chiesi Farmaceutici S.p.A. Elfabrio summary of product characterisitcs. Accessed 8-Aug-2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elfabrio-epar-product-information_en.pdf. Accessed 8 Aug 2024."},{"issue":"31","key":"684_CR55","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1016\/j.vaccine.2023.06.009","volume":"41","author":"GT Kozma","year":"2023","unstructured":"Kozma GT, M\u00e9sz\u00e1ros T, Ber\u00e9nyi P, et al. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG. Vaccine. 2023;41(31):4561\u201370. https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.009.","journal-title":"Vaccine"},{"issue":"15","key":"684_CR56","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.4155\/bio.15.112","volume":"7","author":"M Krishna","year":"2015","unstructured":"Krishna M, Palme H, Duo J, et al. Development and characterization of antibody reagents to assess anti-PEG IgG antibodies in clinical samples. Bioanalysis. 2015;7(15):1869\u201383. https:\/\/doi.org\/10.4155\/bio.15.112.","journal-title":"Bioanalysis"},{"issue":"5","key":"684_CR57","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2019.242289","volume":"106","author":"RQH Kloos","year":"2021","unstructured":"Kloos RQH, Math\u00f4t R, Pieters R, van der Sluis IM. Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. Haematologica. 2021;106(5):1254\u201361. https:\/\/doi.org\/10.3324\/haematol.2019.242289.","journal-title":"Haematologica"},{"issue":"1","key":"684_CR58","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/bjh.18158","volume":"198","author":"J Sidhu","year":"2022","unstructured":"Sidhu J, Masurekar AN, Gogoi MP, et al. Activity and toxicity of intramuscular 1000 iu\/m(2) polyethylene glycol-E. coli l-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials. Br J Haematol. 2022;198(1):142\u201350. https:\/\/doi.org\/10.1111\/bjh.18158.","journal-title":"Br J Haematol"},{"issue":"11","key":"684_CR59","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1007\/s00277-023-05373-5","volume":"102","author":"TD Coe-Eisenberg","year":"2023","unstructured":"Coe-Eisenberg TD, Perissinotti AJ, Marini BL, et al. Evaluating the efficacy and toxicity of dose adjusted pegylated l-asparaginase in combination with therapeutic drug monitoring. Ann Hematol. 2023;102(11):3133\u201341. https:\/\/doi.org\/10.1007\/s00277-023-05373-5.","journal-title":"Ann Hematol"},{"key":"684_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02153-6","author":"M Dam","year":"2024","unstructured":"Dam M, Centanni M, Friberg LE, et al. Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia. Leukemia. 2024. https:\/\/doi.org\/10.1038\/s41375-024-02153-6.","journal-title":"Leukemia"},{"issue":"12","key":"684_CR61","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3748\/wjg.v11.i12.1769","volume":"11","author":"MR Kraus","year":"2005","unstructured":"Kraus MR, Sch\u00e4fer A, Csef H, Scheurlen M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol. 2005;11(12):1769\u201374. https:\/\/doi.org\/10.3748\/wjg.v11.i12.1769.","journal-title":"World J Gastroenterol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00684-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00684-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00684-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T19:04:44Z","timestamp":1730487884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00684-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00684-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"27 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sanofi provided the funding for the study and for the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C.L. is employed by Sanofi and may own Sanofi stock or stock options. During the course of the research,\u00a0M.M. was employed by Sanofi and was a shareholder.\u00a0Y.K. and V.P. are employed by Evidera, a part of Thermo Fisher Scientific which provides consulting and other research services to pharmaceutical, medical device, and related organizations. In their salaried positions, they work with a variety of companies and organizations and are precluded from receiving payment or honoraria directly from these organizations for services rendered. Evidera received funding from Sanofi to participate in the development of this manuscript. C.W. has received personal fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CSL-Vifor, Eli Lilly and Company, GlaxoSmithKline, MSD, Novo Nordisk, and Sanofi outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"C.L. and M.M. conceived the overall concept, contributed to the writing of the manuscript, provided expert review, and supervised manuscript development. V.P. conceived of the literature review design, conducted the search, and participated in the screening and data extraction. Y.K. did the majority of the writing and participated in the screening and data extraction. C.W. provided expert opinion. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}